head shot image

Paul R Hutson, PharmD, MS

Professor (CHS)

Prof. Hutson’s present research is focused on the safety and therapeutic use of psilocybin for various serious diseases that are resistant to other therapies. The entheogen (or psychedelic) psilocybin has shown promise in treating addiction, depression, and anxiety in recent studies. Dr. Hutson’s work with this compound includes pharmacokinetic studies of escalating doses in normal volunteers, and seeks to extend the clinical trials to patients with cancer distress, eating disorders or addiction. An excellent article on the current clinical research here and elsewhere is available at:

Dr. Hutson also provides population pharmacokinetic modeling services using NONMEM and S-ADAPT to University of Wisconsin researchers through the UW Institute for Clinical and Translational Research. Collaborative activities in pharmacokinetic modeling include sparse sampling in murine research cohorts, porcine retinoid deprivation/supplementation, and bioengineering devices. UW researchers seeking consultation or pharmacokinetic modeling services are welcome to contact Paul Hutson directly, or through the UW ICTR Biostatistics and Research Design Resource:

Background: Paul Hutson, whose baccalaureate and master's degrees are in biochemistry and chemistry respectively, completed an oncology/pharmacokinetics fellowship at St. Jude Children's Research Hospital in Memphis. He was a faculty member at the University of Illinois for five years before moving to Madison in 1988. He now practices pharmacy with the oncology and palliative care group at the UW Hospital and Clinics and is an Associate Member of the UW Carbone Cancer Center. His course offerings at the School of Pharmacy are Clinical Pharmacokinetics, Pediatric Pharmacotherapy, Seminars in Oncology Pharmacotherapy, and the Appropriate Use of Drugs of Abuse.  He supervises a non-clinical Advanced Pharmacy Practice Experience (APPE) in basic pharmacometrics.

Prof. Hutson is the principal investigator for a recent study of the safety and pharmacokinetics of escalating doses of psilocybin in normal healthy adults. This study was designed to support the extension of recent Phase II trials in patients with advanced cancer suffering from severe anxiety or depression to collaborative Phase III trials. He is also a co-investigator advising on the design and implementation of additional Phase I clinical trials at the University of Wisconsin School of Pharmacy to explore the safety and utility of psilocybin in the treatment of persons with opioid use disorder.

Professional Interests:

  • Drug Development - Psilocybin, MDMA
  • Population Pharmacokinetic / Pharmacodynamic Modeling
  • Cancer-related Palliative Care
  • Therapeutic Opiate Use / Global Regulatory Barriers



  • BS 1975 Biochemistry - University of California-Los Angeles
  • MS 1976 Chemistry - University of Washington
  • BS Pharm. 1979 Pharmacy - University of Washington
  • PharmD 1981 - University of Tennessee

728-555 Pharmacotherapy (Clinical Pharmacokinetics)

728-657 Seminars in Pediatrics

728-490 Seminars in Oncology Pharmacotherapy

726-640 Appropriate Use of Drugs of Abuse

728-656 Oncology Pharmacotherapy

Highlighted Publications:
  • Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clin Pharmacokinet. 2017 Mar 28. doi: 10.1007/s40262-017-0540-6. PubMed PMID: 28353056.
  • Hutson P, Backonja M, Knurr H. Intravenous Lidocaine for Neuropathic Pain: A Retrospective Analysis of Tolerability and Efficacy. Pain Med. 2014 Dec 19. PubMed PMID: 25530475.
  • Wong L, Hutson PR, Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2015 Ja 75(1):23-32. doi: 10.1002/pros.22886. Epub 2014 Oct 4. PubMed PMID: 25284058; PubMed Central PMCID: PMC4257860.
  • Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct;74(4):875-82. PubMed PMID: 25168296; PubMed Central PMCID: PMC4175433.
  • Wong L, Hutson PR, Bushman W. Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoS One. 2014 Jun 20;9(6):e100770. doi: 10.1371/journal.pone.0100770. eCollection 2014. PubMed PMID: 24950301; PubMed Central PMCID: PMC4065064.
  • Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, McGregor LM, Otto M, Gillies SD, Handgretinger R, Santana VM. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol. 2014;10:1445-52. PMID: 24711551
  • Zhang Y, Jiang H, Hutson P. Stability of acetyl-1-carnitine in 5% dextrose using a high-performance liquid chromatography-mass spectrometry times 2 method. Int J Pharm Compd. 2012; 16:170-3. PMID: 23050330
  • Zhang Y, Scarlett C, Hutson P. Stability of carboplatin, paclitaxel, and docetaxel with acetyl-l-carnitine during simulated Y-site administration. Int J Pharm Compd. 2012; 16: 82-5. PMID: 23050317
  • Surles RL, Hutson PR, Valentine AL, Miles JP, Tanumihardjo SA. 3,4-didehydroretinol kinetics differ Turing lactation in sows on a retinol depletion regimen and the serum:milk 3,4-didehydroretinol:retinol ratios are correlated. J Nutr 2011; 141: 554-9. PMID: 21310863
  • Rose WE, Knier RM, Hutson PR. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus. J Antimicrob Chemother. 2010 Oct;65:2149-54. PMID: 20693174
  • Engle DB, Belisle JA, Gubbels JA, Petrie SE, Hutson PR, Kushner DM, Patankar MS. Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. Gynecol Oncol. 2009;112:631-6. PMID: 19263582
  • Lipinski RJ, Hutson PR, Hannam PW, Nydza RJ, Washington IM, Moore RW, Girdaukas GG, Peterson RE, Bushman W. Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the hedgehog signaling antagonist cyclopamine in the mouse. Toxicol Sci. 2008;104:189-97. PMID: 18411234
  • Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol. 2008;62:373-7. PMID: 17922273
  • Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. The Effect of Fluoroquinolone Antibiotics on Growing Cartilage in the Lamb Model. J Ped Ortho 2008; 2009; 29: 189-95. PMID: 19352246
  • Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH. Phase I study of docetaxel and topotecan in patients with advanced malignancies. J Oncol Pharm Pract. 2005;11:131-8. PMID: 16595064
  • Hutson PR, Love RR, Havighurst TC, Rogers E, Cleary JF., Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer. Clin Cancer Res 2005; 11: 8722-7. PMID: 16361559
  • Mould DR, Holford NH, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002;71:334-48. PMID: 12011819